Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.
Commentary|Articles|October 14, 2026
Supplements and Featured Publications
- 2026 ESMO Congress: Focus on Gynecologic Malignancies
- Volume 1
- Issue 1
Long-Term and Novel ADC Data Dominate Top Gynecologic Cancer Abstracts at ESMO 2026
Author(s)Riley Kandel
Fact checked by: Chris Ryan
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
As anticipation builds for the
Related to this article
INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.
Patient-reported outcomes from the phase 3 lidERA trial show preserved functioning and less frequent joint pain with giredestrant vs standard endocrine therapy.
Exploratory subgroup analyses of the phase 2 DOVACC trial suggested a possible signal with the triplet in HRD-negative and PARP inhibitor–naive disease.
Niraparib/Dostarlimab Plus CRT Displays Efficacy but Has Toxicity Concerns in Locally Advanced HNSCC
Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.
Updated FONTANA data show torvu-sam activity across FRα expression levels in platinum-resistant ovarian cancer.
In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.
Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.
Advertisement
Advertisement